Tonix Pharma Publishes Study on TNX-1700 Efficacy

Don’t Miss TipRanks’ Half-Year Sale

Tonix Pharma ( (TNXP) ) has shared an announcement.

On July 2, 2025, Tonix Pharmaceuticals announced the publication of a collaborative study with Columbia University’s Medical School in the journal Cancer Cell. The study demonstrates that the murine version of their drug, TNX-1700, increased survival and decreased metastases in animal models of gastric cancer, suggesting potential for overcoming resistance to anti-PD-1 immunotherapy in gastric and other tumors.

The most recent analyst rating on (TNXP) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.

Spark’s Take on TNXP Stock

According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.

Tonix Pharma benefits from strong corporate events and technical momentum, but is hindered by weak financial performance and valuation metrics. Continued innovation and strategic developments are promising, but profitability challenges remain critical.

To see Spark’s full report on TNXP stock, click here.

More about Tonix Pharma

Tonix Pharmaceuticals Holding Corp. operates in the pharmaceutical industry, focusing on the development of innovative therapeutics. The company is particularly involved in creating treatments for various cancers, including gastric and colorectal cancers, leveraging fusion proteins like TNX-1700.

Average Trading Volume: 940,853

Technical Sentiment Signal: Sell

Current Market Cap: $274.4M

See more data about TNXP stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

No Byline Policy

Editorial Guidelines

Corrections Policy

Source